Exploring the implications of FDA’s renewed focus and commitment to expand the use of accelerated approval for gene therapy products.
Emily Marden, JD
Advertisement
Senior Counsel, Sidley Austin LLP
Articles by Emily Marden, JD
Advertisement
Latest Updated Articles
Accelerated Approval and the Promise of Gene TherapyPublished: September 27th 2023 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
FDA Outlines New Superiority Standard for Future CAR-T Approvals
2
2025 Veeva R&D and Quality Summit: Advancing Site Efficiency and Collaboration in the Next Era of Clinical Trials
3
ACT Brief: Governance-Driven eCOA Acceleration, Site Operations Innovation, and New Momentum for Earlier CAR-T
4
Partners for Success: Governance Best Practices to Streamline eCOA Trial Launch
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
